Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 03:00PM GMT
Release Date Price: $136.3 (+0.38%)
Jason Matthew Gerberry;Daniel N. Swisher
BofA Merrill Lynch, Research Division - MD in US Equity Research;

Good morning, everybody. Thank you for joining us at Bank of America's Annual Healthcare Conference. My name is Jason Gerberry. I'm the U.S. pharma analyst here at Bank of America. I'm pleased to be introducing our first company presenter, Jazz Pharmaceuticals. I'm joined by Dan Swisher, President and Chief Operating Officer; and Kathy Littrell from Investor Relations. So thank you both for joining us at the conference. Jazz is a mid-cap-sized commercial-stage sleep and hematology oncology-focused company. And so I think right now, probably the focus for investors is probably on the new product launches that the company has. So as I kind of think about some of the questions that I have for fireside chat today, I really wanted to focus on some of the new launches and how you guys are thinking about those in positioning relative to the existing competitive set. So maybe if you want to open with any kind of just prepared remarks or if you want to jump into the Q&A?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot